TY - JOUR
T1 - Midazolam as an adjunctive therapy for capture myopathy in Bar-tailed Godwits (Limosa lapponica baueri) with prognostic indicators
AU - Ward, Janelle M.
AU - Gartrell, Brett D.
AU - Conklin, Jesse R.
AU - Battley, Phil F.
PY - 2011
Y1 - 2011
N2 - Capture myopathy is a complication of capture and handling in many species of
birds and mammals. Muscular necrosis leads to ataxia, paralysis, and pain, whereas metabolic disturbances can result in death. We conducted an opportunistic clinical trial on Bar-tailed Godwits (Limosa lapponica baueri) that developed capture myopathy after a cannon-net
capture in New Zealand in October 2008. We assessed the beneficial effects of midazolam, a benzodiazepine with the effects of anxiolysis, muscle relaxation, and sedation, in the adjunctive
treatment of capture myopathy. Physical and biochemical parameters were analyzed retrospectively
for their potential as indicators for survival until release. Birds (n=16) were treated
with subcutaneous fluid therapy, a nonsteroidal anti-inflammatory (meloxicam), gavage
feeding, and sling therapy twice daily. The treatment group (n=8) was treated twice daily
with intramuscular midazolam injections, 1.5 mg/kg. Surviving godwits were released over 1–9 days, with 6 of 8 treated birds (75%) surviving to release, compared with 3 of 8 controls
(38%). Inability to counteract weight loss in captivity was the most significant problem for both
groups. Lack of waterproofing and predation were contributing causes of death for at least two
godwits after release. Birds treated with midazolam showed subjective benefits including
improved tolerance of handling and sling therapy. Clinical parameters (change in body mass,
packed cell volume [PCV], plasma creatine kinase [CK], aspartate aminotransferase [AST],
total protein, and uric acid [UA] over time) were not statistically different between groups,
although peak average values for CK, AST, and UA were lower in the treatment group. Decline
in body mass (%), PCV, final plasma UA, and peak plasma CK were the most useful prognostic
indicators. Midazolam shows potential as an ancillary treatment for capture myopathy in birds
and is worthy of continued study and use.
AB - Capture myopathy is a complication of capture and handling in many species of
birds and mammals. Muscular necrosis leads to ataxia, paralysis, and pain, whereas metabolic disturbances can result in death. We conducted an opportunistic clinical trial on Bar-tailed Godwits (Limosa lapponica baueri) that developed capture myopathy after a cannon-net
capture in New Zealand in October 2008. We assessed the beneficial effects of midazolam, a benzodiazepine with the effects of anxiolysis, muscle relaxation, and sedation, in the adjunctive
treatment of capture myopathy. Physical and biochemical parameters were analyzed retrospectively
for their potential as indicators for survival until release. Birds (n=16) were treated
with subcutaneous fluid therapy, a nonsteroidal anti-inflammatory (meloxicam), gavage
feeding, and sling therapy twice daily. The treatment group (n=8) was treated twice daily
with intramuscular midazolam injections, 1.5 mg/kg. Surviving godwits were released over 1–9 days, with 6 of 8 treated birds (75%) surviving to release, compared with 3 of 8 controls
(38%). Inability to counteract weight loss in captivity was the most significant problem for both
groups. Lack of waterproofing and predation were contributing causes of death for at least two
godwits after release. Birds treated with midazolam showed subjective benefits including
improved tolerance of handling and sling therapy. Clinical parameters (change in body mass,
packed cell volume [PCV], plasma creatine kinase [CK], aspartate aminotransferase [AST],
total protein, and uric acid [UA] over time) were not statistically different between groups,
although peak average values for CK, AST, and UA were lower in the treatment group. Decline
in body mass (%), PCV, final plasma UA, and peak plasma CK were the most useful prognostic
indicators. Midazolam shows potential as an ancillary treatment for capture myopathy in birds
and is worthy of continued study and use.
M3 - Article
SN - 0090-3558
VL - 47
SP - 925
EP - 935
JO - Journal of wildlife diseases
JF - Journal of wildlife diseases
IS - 4
ER -